Drug approval status and recommendations for listing on public formularies: a Canadian cohort analysis.

ABSTRACT:

Objectives

Investigate if the recommendations by the Common Drug Review (CDR) and the pan-Canadian Oncology Drug Review (pCODR) to provincial, territorial and federal drug plans about whether to list non-oncology and oncology drug-indication combinations on their formularies are associated with whether the drug-indication combination was approved via the standard evidence pathway or the Notice of Compliance with conditions (NOC/c-limited evidence) pathway.

Design

Cohort study.

Data sources

Websites of the CDR and pCODR up to the end of 31 March 2017; journal articles evaluating drugs approved through the NOC/c pathway, the NOC database, the NOC/c website and the Summary Basis of Decision website.

Interventions

Recommendations by the CDR and pCODR.

Primary an

SUBMITTER: Lexchin J 

PROVIDER: S-EPMC5665246 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature